Location: 3200 MSRB3
Lab Phone: 734-936-3440
Email: devond@umich.edu
Born and raised in Seattle, WA, Devon moved to the Bay Area to study Molecular and Cell Biology at the University of California, Berkeley. While studying at UC Berkeley, Devon worked as an undergraduate research assistant at the University of California, San Francisco studying compound activity against prion virility. Upon graduating (with a minor in French) in 2015, she returned to Seattle to work as a research assistant at the Infectious Disease Research Institute (IDRI) in the Tuberculosis Drug Discovery group. There, she primarily worked on target identification, isolating compound-resistant tuberculosis mutants and characterizing their mutant genome and associated phenotypes. After moving to Ann Arbor in 2018 (with her two cats) to pursue a PhD through the University of Michigan PIBS, Devon joined the Baldridge lab and the Cell and Molecular Biology program in May 2019. Devon’s current project looks beyond the ER to investigate a Golgi-specific protein quality control mechanisms called the Dsc complex by developing a functional genomic screen.
Efficacy and Improved Resistance Potential of a Cofactor-Independent InhA Inhibitor of Mycobacterium tuberculosis in the C3HeB/FeJ Mouse Model.
Robertson GT, Ektnitphong VA, Scherman MS, McNeil MB, Dennison D, Korkegian A, Smith AJ, Halladay J, Carter DS, Xia Y, Zhou Y, Choi W, Berry PW, Mao W, Hernandez V, Alley MRK, Parish T, Lenaerts AJ
Antimicrobial Agents and Chemotherapy, 2019, 63 (4)
View on PubMed »A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
Bonnett SA, Dennison D, Files M, Bajpai A, Parish T
PloS One, 2018, 13 (10), e0198059
View More »Mutations in MmpL3 alter membrane potential, hydrophobicity and antibiotic susceptibility in Mycobacterium smegmatis.
McNeil MB, Dennison D, Parish T
Microbiology (Reading, England), 2017, 163 (7), 1065-1070
View on PubMed »<i>In Vitro</i> Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.
McNeil MB, Dennison DD, Shelton CD, Parish T
Antimicrobial Agents and Chemotherapy, 2017, 61 (10)
View More »Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.
McNeil MB, Dennison D, Shelton C, Flint L, Korkegian A, Parish T
Tuberculosis (Edinburgh, Scotland), 2017, 107, 133-136
View More »In Vitro Evaluation of Novel Nitazoxanide Derivatives against <i>Mycobacterium tuberculosis</i>.
Odingo J, Bailey MA, Files M, Early JV, Alling T, Dennison D, Bowman J, Dalai S, Kumar N, Cramer J, Masquelin T, Hipskind PA, Parish T
ACS Omega, 2017, 2 (9), 5873-5890
View More »View on PubMed »